Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-09

Entrada Therapeutics (TRDA)

CEO Dipal Doshi was paid $3,837,737 in fiscal year 2025, ↓ down 1.4% from fiscal year 2024 (SEC filing 0001689375-26-000021 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,837,737 ↓
Dipal Doshi total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Dipal Doshi (Chief Executive Officer), FY2025 total compensation $3,837,737 (base salary $635,000) [exec_comp, SEC accession 0001689375-26-000021, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

TRDA's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Dipal Doshi$635,000$0$1,387,428$1,452,059$349,250$0$14,000$3,837,737
Chief Executive Officer
Natarajan Sethuraman520,0000725,952760,363234,000014,0002,254,315
President of Research and Development
Nathan Dowden499,2000725,952760,363224,640013,3422,223,497
President and Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Dipal Doshi$3,837,737$3,891,503—↓ −53,766
Natarajan Sethuraman2,254,3151,962,700—↑ +291,615
Nathan Dowden2,223,4972,460,688—↓ −237,191

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Entrada Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TRDA reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against TRDA
6 companies name TRDA as a compensation peer

The list of companies that name TRDA as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Dipal DoshiCEO$3,837,737
Natarajan SethuramanPresident$2,254,315
Nathan DowdenPresident$2,223,497
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Bernhardt Zeiher, M.DIndependent Director$150,680
Gina ChapmanIndependent Director$157,553
Kush M. Parmar, M.D., Ph.DChair of the Board$202,597
Maha Radhakrishnan, M.DIndependent Director$230,927
Mary ThistleIndependent Director$167,427
Peter S. Kim, Ph.DDirector$144,388
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Nathan DowdenPresident & COO2026-05-04D15,000$15$229,953CommonForm 4 ↗
Natarajan SethuramanPresident, Research & Develop.2026-05-04D25,90715398,810CommonForm 4 ↗
Nathan DowdenPresident & COO2026-05-04D15,00000Derivative, Class A CommonForm 4 ↗
Nathan DowdenPresident & COO2026-05-04A15,000226,100CommonForm 4 ↗
Bernhardt G. ZeiherDirector2026-05-20A5,000629,316Common, indirectForm 4 ↗
Bernhardt G. ZeiherDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Mary ThistleDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Maha RadhakrishnanDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Gina ChapmanDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Peter S. KimDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Kush ParmarDirector2026-06-10A19,00000Derivative, Class A CommonForm 4 ↗
Kush ParmarDirector2026-07-30D114,7567795,259Common, indirectForm 4 ↗
5AM Ventures V, L.P.Greater-than-10% holder2026-07-30D114,7567795,259Common, indirectForm 4 ↗
Kush ParmarDirector2026-07-31D1,718711,768CommonForm 4 ↗
5AM Ventures V, L.P.Greater-than-10% holder2026-07-31D1,718711,768Common, indirectForm 4 ↗
5AM Ventures V, L.P.Greater-than-10% holder2026-08-06D10,494773,458Common, indirectForm 4 ↗
Kush ParmarDirector2026-08-06D10,494773,458Common, indirectForm 4 ↗
5AM Ventures V, L.P.Greater-than-10% holder2026-08-07D52,3177358,371Common, indirectForm 4 ↗
Kush ParmarDirector2026-08-07D52,3177358,371CommonForm 4 ↗
Kush ParmarDirector2026-08-10D92,4447647,108Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-24D21,6237158,713Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-24D21,6237158,713Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-25D26,5228199,976Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-25D26,5228199,976Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-26D14,5697102,857Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-26D14,5697102,857Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-27D38,9227280,238Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-27D38,9227280,238Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-28D3,733726,168Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-28D3,733726,168Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-08-31D44,2597309,370Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-08-31D44,2597309,370Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-01D29,0887205,361Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-01D29,0887205,361Common, indirectForm 4 ↗
Dipal DoshiDirector2026-09-02D8,724762,323CommonForm 4 ↗
Natarajan SethuramanPresident, Research & Develop.2026-09-02D2,079714,852CommonForm 4 ↗
Kory James WentworthChief Financial Officer2026-09-02D1,733712,380CommonForm 4 ↗
Nathan DowdenPresident & COO2026-09-02D2,528718,060CommonForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-02D25,1317180,692Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-02D25,1317180,692Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-03D32,2637231,326Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-03D32,2637231,326Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-04D38,5007273,735Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-04D38,5007273,735Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-08D192,50071,426,425Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-08D192,50071,426,425Common, indirectForm 4 ↗
MPM BioVentures 2014, L.P.Greater-than-10% holder2026-09-09D28,8377205,608Common, indirectForm 4 ↗
MPM BIOVENTURES 2018, L.P.Greater-than-10% holder2026-09-09D28,8377205,608Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Nathan DowdenOption—————$760,363
Dipal DoshiPSU—————1,387,428
Natarajan SethuramanOption—————760,363
Dipal DoshiOption—————1,452,059
Nathan DowdenPSU—————725,952
Natarajan SethuramanPSU—————725,952
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Nathan Dowden$0$725,952$760,36348.8%
Dipal Doshi01,387,4281,452,05948.9%
Natarajan Sethuraman0725,952760,36348.8%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Natarajan SethuramanOption9,40615.41—
Dipal DoshiOption11,34411.57—
Nathan DowdenRSU24,825—255,201
Natarajan SethuramanRSU7,100—72,988
Nathan DowdenRSU7,100—72,988
Natarajan SethuramanOption4,34511.57—
Natarajan SethuramanRSU80,000—822,400
Nathan DowdenRSU2,816—28,948
Nathan DowdenOption9,40615.41—
Nathan DowdenOption28,18113.73—
Dipal DoshiRSU116,200—1,194,536
Dipal DoshiRSU100,000—1,028,000
Nathan DowdenRSU30,000—308,400
Dipal DoshiRSU24,825—255,201
Dipal DoshiRSU3,781—38,869
Nathan DowdenRSU1,408—14,474
Dipal DoshiOption32,92215.41—
Natarajan SethuramanOption5,07012—
Dipal DoshiRSU78,525—807,237
Natarajan SethuramanRSU33,075—340,011
Dipal DoshiRSU7,562—77,737
Natarajan SethuramanRSU1,448—14,885
Dipal DoshiOption13,23412—
Nathan DowdenOption6,71912.25—
Natarajan SethuramanRSU2,897—29,781
Natarajan SethuramanOption90,80011.94—
Natarajan SethuramanOption37,57513.73—
Nathan DowdenOption4,22311.57—
Nathan DowdenOption4,92712—
Nathan DowdenOption90,80011.94—
Dipal DoshiOption23,51612.25—
Dipal DoshiOption89,15613.73—
Dipal DoshiOption173,40011.94—
Nathan DowdenRSU60,000—616,800
Nathan DowdenRSU60,800—625,024
Natarajan SethuramanOption6,71912.25—
Natarajan SethuramanRSU60,800—625,024
05

Incentive-plan design — the Compensation Discussion & Analysis

Compensation for named executive officers consists of a combination of base salary, cash bonuses, and long-term incentive compensation in the form of stock options, RSUs and PSUs, designed to be competitive and aligned with the company's business and executive talent requirements.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantPay Governance
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Maha Radhakrishnan, M.DIndependent · Audit · Newly elected$28,538$0$202,388—$0$230,927
Kush M. Parmar, M.D., Ph.DIndependent · Board Chair · Compensation (Chair) · Nominating/Governance (Chair)98,2090104,388—0202,597
Mary ThistleIndependent · Audit (Chair) · Compensation63,0380104,388—0167,427
Gina ChapmanIndependent · Audit · Nominating/Governance53,1650104,388——157,553
Bernhardt Zeiher, M.DIndependent · Compensation46,2910104,388—0150,680
Peter S. Kim, Ph.DNot independent40,0000104,388—0144,388
Dipal DoshiEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 9,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$329,241
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$329,241

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Entrada Therapeutics2025Dipal Doshi$635,000$1,387,428$1,452,059$349,250$3,837,737

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Entrada Therapeutics in fiscal 2025?
As disclosed, Dipal Doshi (Chief Executive Officer) was the highest-paid executive at Entrada Therapeutics in fiscal 2025, with total compensation of $3,837,737.
How much does Entrada Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Entrada Therapeutics reported total board compensation of $329,241 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Dipal DoshiDEF 14A2026-04-240001689375-26-000021Section “2025 Summary Compensation Table”. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900
2Section 01, Natarajan SethuramanDEF 14A2026-04-240001689375-26-000021Section “2025 Summary Compensation Table”. As printed: 2,254,315. Filing ↗machine: t12 · r4 · c14 · span 341380–341389
3Section 01, Nathan DowdenDEF 14A2026-04-240001689375-26-000021Section “2025 Summary Compensation Table”. As printed: 2,223,497. Filing ↗machine: t12 · r6 · c14 · span 345914–345923
4Section 03, Nathan Dowden OptionDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c8 · span 344988–344995
5Section 03, Dipal Doshi PSUDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c6 · span 335548–335557
6Section 03, Natarajan Sethuraman OptionDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c8 · span 340604–340611
7Section 03, Dipal Doshi OptionDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r2 · c8 · span 335885–335894
8Section 03, Nathan Dowden PSUDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r6 · c6 · span 344679–344686
9Section 03, Natarajan Sethuraman PSUDEF 14A2026-04-240001689375-26-000021Section “ALL OTHER COMPENSATION (” · grants of plan-based awards table. Filing ↗machine: t12 · r4 · c6 · span 340345–340352
10Section 07, pay ratio10-K2026-02-260001689375-26-000011Section “CEO Pay Ratio”. As printed: —. Filing ↗
11Section 08, Maha Radhakrishnan, M.DDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 230,927. Filing ↗machine: span 529796–530012
12Section 08, Kush M. Parmar, M.D., Ph.DDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 202,597. Filing ↗machine: span 525189–525430
13Section 08, Mary ThistleDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 167,427. Filing ↗machine: t16 · r3 · c7 · span 523556–523772
14Section 08, Gina ChapmanDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 157,553. Filing ↗machine: t16 · r6 · c7 · span 528305–528546
15Section 08, Bernhardt Zeiher, M.DDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 150,680. Filing ↗machine: span 526674–526890
16Section 08, Peter S. Kim, Ph.DDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 144,388. Filing ↗machine: span 522044–522316
17Section 08, Dipal DoshiDEF 14A2026-04-240001689375-26-000021Section “Director Compensation”. As printed: 0. Filing ↗
18Section 02, Nathan Dowden 2026-05-04Form 42026-05-040001873392-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Natarajan Sethuraman 2026-05-04Form 42026-05-040001873394-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Nathan Dowden 2026-05-04Form 42026-05-040001873392-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Nathan Dowden 2026-05-04Form 42026-05-040001873392-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Bernhardt G. Zeiher 2026-05-20Form 42026-05-210001689375-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Bernhardt G. Zeiher 2026-06-10Form 42026-06-120001689375-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Mary Thistle 2026-06-10Form 42026-06-120001689375-26-000036Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Maha Radhakrishnan 2026-06-10Form 42026-06-120002013423-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Gina Chapman 2026-06-10Form 42026-06-120001689375-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Peter S. Kim 2026-06-10Form 42026-06-120001689375-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Kush Parmar 2026-06-10Form 42026-06-120001689375-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Kush Parmar 2026-07-30Form 42026-08-030001664281-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, 5AM Ventures V, L.P. 2026-07-30Form 42026-08-030001231919-26-000822Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Kush Parmar 2026-07-31Form 42026-08-030001664281-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, 5AM Ventures V, L.P. 2026-07-31Form 42026-08-030001231919-26-000822Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, 5AM Ventures V, L.P. 2026-08-06Form 42026-08-100001231919-26-000854Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Kush Parmar 2026-08-06Form 42026-08-100001664281-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, 5AM Ventures V, L.P. 2026-08-07Form 42026-08-100001231919-26-000854Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Kush Parmar 2026-08-07Form 42026-08-100001664281-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Kush Parmar 2026-08-10Form 42026-08-100001664281-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-24Form 42026-08-260001231919-26-001106Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, MPM BioVentures 2014, L.P. 2026-08-24Form 42026-08-260001231919-26-001107Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, MPM BioVentures 2014, L.P. 2026-08-25Form 42026-08-260001231919-26-001107Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-25Form 42026-08-260001231919-26-001106Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, MPM BioVentures 2014, L.P. 2026-08-26Form 42026-08-260001231919-26-001107Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-26Form 42026-08-260001231919-26-001106Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, MPM BioVentures 2014, L.P. 2026-08-27Form 42026-08-310001231919-26-001135Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-27Form 42026-08-310001231919-26-001136Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-28Form 42026-08-310001231919-26-001136Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, MPM BioVentures 2014, L.P. 2026-08-28Form 42026-08-310001231919-26-001135Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, MPM BioVentures 2014, L.P. 2026-08-31Form 42026-08-310001231919-26-001135Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, MPM BIOVENTURES 2018, L.P. 2026-08-31Form 42026-08-310001231919-26-001136Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, MPM BioVentures 2014, L.P. 2026-09-01Form 42026-09-030001231919-26-001143Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-01Form 42026-09-030001231919-26-001144Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Dipal Doshi 2026-09-02Form 42026-09-030001613084-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Natarajan Sethuraman 2026-09-02Form 42026-09-030001873394-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kory James Wentworth 2026-09-02Form 42026-09-030001725663-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Nathan Dowden 2026-09-02Form 42026-09-030001873392-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, MPM BioVentures 2014, L.P. 2026-09-02Form 42026-09-030001231919-26-001143Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-02Form 42026-09-030001231919-26-001144Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-03Form 42026-09-030001231919-26-001144Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, MPM BioVentures 2014, L.P. 2026-09-03Form 42026-09-030001231919-26-001143Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, MPM BioVentures 2014, L.P. 2026-09-04Form 42026-09-090001231919-26-001155Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-04Form 42026-09-090001231919-26-001156Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-08Form 42026-09-090001231919-26-001156Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, MPM BioVentures 2014, L.P. 2026-09-08Form 42026-09-090001231919-26-001155Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, MPM BioVentures 2014, L.P. 2026-09-09Form 42026-09-090001231919-26-001155Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, MPM BIOVENTURES 2018, L.P. 2026-09-09Form 42026-09-090001231919-26-001156Insider equity transaction reported since the proxy statement. Filing ↗
66Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
67Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
68Section 09b board cost (computed)Computed——Cash 329,241 + equity 0 + all other 0 = 329,241, summed across the director compensation table rows.machine: formula: Σ = 329,241
69Entrada Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-240001689375-26-000021CEO total compensation as printed in Entrada Therapeutics's own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.